B+
Bull case
25%
Probability
Target price
$32.00
+256.7% vs current
KURA
Kura OncologyANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$15.00
+67.2% vs current
B-
Bear case
25%
Probability
Target price
$4.50
-49.8% vs current
AI sentiment snapshot
Latest data as of 2026-06-02
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+100.0
Score
AI commentary
The immediate post-Q1 reaction was modestly positive, with secondary coverage noting the shares rose about 4.5% after the report, but the more important takeaway was mixed: strong launch metrics and broad payer coverage were offset by lower post-earnings revenue estimates. Coverage remains thin, the target range is wide, and the stock is still driven mainly by launch read-through and upcoming AML data rather than stable fundamentals.
RankAlpha Sentiment Codex - 2026-06-02
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-12eventFirst full-quarter KOMZIFTI launch showed real early tractionMedium impact
Kura reported $5.8 million in KOMZIFTI net product revenue in its first full quarter of commercialization, with 85 new patient starts, 157 total prescriptions, >93% payer coverage across more than 12 million lives, and $580.8 million of cash, cash equivalents and short-term investments plus $180 million of anticipated collaboration payments to support the AML program through first topline KOMET-017 Phase 3 results. [#SEC-8K-2026-05-12]
2026-12-31catalyst2026 AML readouts can validate the broader backbone thesisHigh impact
Management said multiple 2026 data readouts are expected across frontline and combination settings, while KOMET-017, KOMET-008, KOMET-007 and the Japanese registrational trial were all advancing with ongoing enrollment. Positive safety, combinability or efficacy data would matter more than near-term revenue for a rerating. [#SEC-8K-2026-05-12]
2026-12-31catalystBalance sheet reduces near-term financing overhangMedium impact
Kura said its cash position plus expected collaboration payments should fund advancement through first topline KOMET-017 Phase 3 results, which lowers near-term dilution risk relative to many small-cap biotech peers. [#SEC-8K-2026-05-12]
Recommendation
N/A
No formal recommendation provided.
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology